Prevention and treatment of graft vessel disease after heart transplantation.
Meiser
B M
BM
Department of Cardiac Surgery and Clinical Chemistry, Ludwig-Maximilians-University Munich, Grosshadern Medical Center, Germany.
Wenke
K
K
Thiery
J
J
Brandl
U
U
Mair
H
H
Kur
F
F
Detter
C
C
Uberfuhr
P
P
Kreuzer
E
E
Seidel
D
D
D000328:Adult; D001161:Arteriosclerosis / Q000517:prevention & control* / Q000628:therapy*; D001781:Blood Component Removal; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006083:Graft Occlusion, Vascular / Q000517:prevention & control* / Q000628:therapy*; D006086:Graft vs Host Disease / Q000517:prevention & control; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D010456:Peptides, Cyclic; D011446:Prospective Studies; D012307:Risk Factors; D019821:Simvastatin; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014019:Tissue Donors
D009842:Oligopeptides; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin